PriceTargets.com logo

Brainstorm Cell Therapeutics - BCLI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $5.00
  • Forecasted Upside: 116.45%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.31 As of 02/6/2023 01:00 AM ET
▼ -0.39 (-14.44%)

This chart shows the closing price for BCLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Brainstorm Cell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCLI

Analyst Price Target is $5.00
▲ +116.45% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Brainstorm Cell Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 116.45% upside from the last price of $2.31.

This chart shows the closing price for BCLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Brainstorm Cell Therapeutics. This rating has held steady since December 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022Maxim GroupLower Target$8.00 ➝ $5.00Low
12/22/2021Dawson JamesReiterated RatingNeutralMedium
2/4/2021Maxim GroupUpgradeHold ➝ Buy$12.00High
11/17/2020Maxim GroupDowngradeBuy ➝ HoldN/A
7/8/2020Maxim GroupBoost TargetBuy$9.00 ➝ $20.00Low
5/8/2020Maxim GroupInitiated CoverageBuy$9.00Medium
11/15/2019Maxim GroupReiterated RatingBuy$9.00Low
10/11/2019Maxim GroupSet TargetBuy$9.00Low
5/14/2019Maxim GroupReiterated RatingBuy$9.00Low
3/28/2019Maxim GroupSet TargetBuy$9.00Low
1/22/2019Maxim GroupReiterated RatingBuy$9.00Medium
12/26/2018Maxim GroupSet TargetBuy$9.00High
12/18/2018Dawson JamesReiterated RatingBuyHigh
12/17/2018Maxim GroupReiterated RatingBuy$9.00High
11/19/2018Maxim GroupSet TargetBuy$9.00High
10/29/2018Maxim GroupSet TargetBuy$9.00High
10/29/2018HC WainwrightSet TargetBuy$11.00High
10/3/2018Maxim GroupSet TargetBuy$9.00Medium
9/18/2018HC WainwrightSet TargetBuy$11.00High
9/13/2018Maxim GroupReiterated RatingBuy$9.00Low
8/27/2018HC WainwrightSet TargetBuy$11.00Low
7/24/2018HC WainwrightSet TargetBuy$11.00High
7/23/2018Maxim GroupSet TargetBuy$9.00Medium
7/8/2018Maxim GroupSet TargetBuy$9.00Low
7/2/2018Maxim GroupSet TargetBuy$9.00Low
6/26/2018HC WainwrightReiterated RatingBuy$11.00Low
6/8/2018HC WainwrightSet TargetBuy$11.00Low
5/29/2018HC WainwrightSet TargetBuy$11.00High
5/25/2018Maxim GroupSet TargetBuy$9.00High
5/15/2018HC WainwrightInitiated CoverageBuy$11.00High
5/14/2018Maxim GroupSet TargetBuy$9.00Low
3/28/2018Maxim GroupSet TargetBuy$9.00High
3/21/2018Maxim GroupSet TargetBuy$9.00Low
3/8/2018Maxim GroupSet TargetBuy$9.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.32 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/10/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/9/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/7/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Brainstorm Cell Therapeutics logo
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
Read More

Today's Range

Now: $2.31
Low: $2.07
High: $2.86

50 Day Range

MA: $1.66
Low: $1.37
High: $2.70

52 Week Range

Now: $2.31
Low: $1.09
High: $4.70

Volume

591,243 shs

Average Volume

267,943 shs

Market Capitalization

$84.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Brainstorm Cell Therapeutics?

The following Wall Street analysts have issued research reports on Brainstorm Cell Therapeutics in the last twelve months: Maxim Group, and StockNews.com.
View the latest analyst ratings for BCLI.

What is the current price target for Brainstorm Cell Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Brainstorm Cell Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 116.5%. Maxim Group has the highest price target set, predicting BCLI will reach $5.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for Brainstorm Cell Therapeutics in the next year.
View the latest price targets for BCLI.

What is the current consensus analyst rating for Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BCLI.

What other companies compete with Brainstorm Cell Therapeutics?

Other companies that are similar to Brainstorm Cell Therapeutics include X4 Pharmaceuticals, Talaris Therapeutics, Orchard Therapeutics, Ambrx Biopharma and Curis. Learn More about companies similar to Brainstorm Cell Therapeutics.

How do I contact Brainstorm Cell Therapeutics' investor relations team?

Brainstorm Cell Therapeutics' physical mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (201) 488-0460 and its investor relations email address is [email protected] The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com. Learn More about contacing Brainstorm Cell Therapeutics investor relations.